Icon

Kisqali - (200 mg; Tablet)

Ribociclib Succinate Novartis
200 mg; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None
Kisqali is a cancer medicine used to treat breast cancer that is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body). It can only be used when the cancer cells have receptors (targets) for certain sex hormones on their surface (HR-positive) and do not have large quantities of another receptor called HER2 (HER2-negative)
Yes
********* ** ******** *** ******, ***** ******* ** ******** ** *** ******** ** -****, ****, ****. **, ** ******** **** **** ** *** ******** *** ****** *** ******* ****** ********** ** ******** ******.
Kisqali Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
********* **** ******* ******* ******* ******* ******* ******* ******* *******
*** **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** *** ********* **** ** *** **, **** *** ********* *** *********
******* ******* **** *** ******* **** *** ******* **** *** ******* **** *** ******* **** *** ******* **** *** ******* **** *** ******* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
********* **** *** \ ********* *** **, **** ******* **** ******* *** **** *** *** ****
*** **** *** \ *** *** **, **** ******* ********* ******** *** ****** *** ****
******* ** \ ** -**- ******* **** *** ******** ** *** **, ****
  1. *** **, **** : * **** ** *** ***** *** ***** *** * *** *********.
  2. *** *, **** : ********* **** ******** ******** ** ***** ****-** ****** **** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, *** ’***
  3. *** **, **** : *** **** ******** ******** ** ***** ****-** ****** **** ******* ’***, ’***, ’***, ’***, *** ’***
  4. *** **, **** : ******** **** ********* **** ************ ** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, *** ’***
  5. *** **, **** : ******** **** *** **** **** ************ ** ******* ’***, ’***, ’***, ’***, *** ’***
  6. *** **, **** : ******** *** ********* ******* ********** ** ******* *****.
  7. *** **, **** : ******* *** ***** ********. ** ** *** *********. ** ** ****** **** *** **** ***** **** ***.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.